Vaxart (OTCMKTS:VXRT) Stock Price Breaks Below 200-Day Moving Average – Time to Sell?

Vaxart, Inc. (OTCMKTS:VXRT)’s stock price crossed below its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $0.59 and traded as low as $0.43. Vaxart shares last traded at $0.45, with a volume of 161,720 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised Vaxart to a “hold” rating in a research report on Thursday, July 9th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat.com, Vaxart currently has a consensus rating of “Hold”.

Vaxart Stock Performance

The company has a market capitalization of $106.50 million, a price-to-earnings ratio of 2.73 and a beta of 1.05. The firm’s 50 day simple moving average is $0.50 and its 200-day simple moving average is $0.58.

Vaxart (OTCMKTS:VXRT) last announced its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.06. The firm had revenue of $27.18 million during the quarter, compared to the consensus estimate of $26.21 million. Vaxart had a return on equity of 53.04% and a net margin of 15.88%. As a group, equities analysts anticipate that Vaxart, Inc. will post -0.68 earnings per share for the current fiscal year.

About Vaxart

Vaxart, Inc is a clinical-stage biotechnology company developing vaccines designed to be administered orally in tablet form rather than by injection. The company’s platform is intended to stimulate immune responses in the nose, mouth and gastrointestinal tract, in addition to systemic immunity, with the goal of improving vaccine administration and potentially limiting the spread of respiratory and enteric infections.

Vaxart’s pipeline has included oral vaccine candidates for norovirus, seasonal influenza and coronavirus infections.